Results from the ACCELERATE outcomes study of Eli Lilly & Co.’s CETP inhibitor evacetrapib suggest that inflammation may have played a role in the trial’s failure, but investigators say it’s really still too early to say what happened.
Inflammation A Clue Left In ACCELERATE CETP Wreckage
Blood pressure and C-reactive protein were modestly increased in the ACCELERATE trial of Lilly’s CETP inhibitor evacetrapib, but what exactly torpedoed the trial is still a mystery.
More from Clinical Trials
• By
The EU Clinical Trials Information System has achieved primary registry designation in the International Clinical Trials Registry Platform in a move that is expected to reduce regulatory burden for companies and help them lower compliance costs by aligning with publication requirements in medical journals.
• By
Newly published insights from a series of European Medicines Agency workshops can guide drug developers in designing development plans that meet the needs of both regulators and health technology assessment bodies.
• By
The new global GCP guideline, ICH E6(R3), enables researchers and clinical trial administrators to tailor their documentation processes, but also opens the door for more scrutiny during GCP inspections.
• By
The European Medicines Agency’s qualification of the AIM-NASH tool is said to signify a major advancement for clinical trials for metabolic dysfunction-associated steatohepatitis. The market size for MASH treatments is expected to grow substantially in the coming years.